Sumitomo Pharma Co Ltd
Sumitomo Pharma's GHG Emissions Data Preview
In 2023, Sumitomo Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions across the value chain).
Sumitomo Pharma has also provided a category-level breakdown for 11 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Market-Based | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Location-Based | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Sumitomo Pharma's Operational Emissions
In 2023, the total operational greenhouse gas (GHG) emissions of Sumitomo Pharma amounted to 53,920 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Sumitomo Pharma decreased by 0.79%, showing that the company has made progress in taking action to reduce the climate impact of its operations.
Sumitomo Pharma's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Sumitomo Pharma's Scope 1 emissions?
In 2023, the total Scope 1 emissions of Sumitomo Pharma were 27,093 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Has Sumitomo Pharma reduced its Scope 1 emissions over time?
Since 2018, Sumitomo Pharma's Scope 1 emissions have increased by 36.53%, reflecting a rising long-term trend in Scope 1 emissions over time.
Compared to the previous year (2022), Sumitomo Pharma's Scope 1 emissions decreased by 2.64%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.
What are Sumitomo Pharma's Scope 2 emissions?
In 2023, Sumitomo Pharma reported Scope 2 greenhouse gas (GHG) emissions of 26,827 tCOâ‚‚e using the market-based method.
Has Sumitomo Pharma reduced its Scope 2 emissions over time?
Since 2018, Sumitomo Pharma's Scope 2 greenhouse gas (GHG) emissions (Market-Based) have decreased by 31.05%, reflecting a declining long-term trend in Scope 2 emissions over time.
Compared to the previous year (2022), Sumitomo Pharma's Scope 2 emissions (Market-Based) have remained relatively stable, indicating that Sumitomo Pharma 's emissions have plateaued with no significant change in its energy consumption footprint.
What methodology does Sumitomo Pharma use for Scope 2 reporting?
In 2023, Sumitomo Pharma reported its Scope 2 emissions using the market-based method.
Sumitomo Pharma's Scope 2 Emissions Over Time
- Total Scope 2 Market-Based
Insights into Sumitomo Pharma's Value Chain Emissions
In 2023, Sumitomo Pharma reported 356,214 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2023 disclosure of Sumitomo Pharma includes a breakdown across 11 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2022, demonstrating consistent Scope 3 emissions reporting coverage year over year.
Sumitomo Pharma's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Sumitomo Pharma's Scope 3 emissions?
In 2023, Sumitomo Pharma reported total Scope 3 emissions of 356,214 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Approximately 98.89% of these emissions originated from upstream activities such as purchased goods and capital goods, while 1.11% came from downstream activities like product use, distribution, and end-of-life treatment.
Compared to the previous year (2022), Sumitomo Pharma's Scope 3 emissions remained relatively stable, indicating that Sumitomo Pharma 's emissions have plateaued with no significant change in its value chain footprint.
What categories of Scope 3 emissions does Sumitomo Pharma disclose?
In 2023, Sumitomo Pharma reported emissions for 11 out of the 15 Scope 3 categories defined by the GHG Protocol.
This reflects a high level of granularity and transparency in the company's emissions reporting.
What are the main sources of Sumitomo Pharma's Scope 3 emissions?
In 2023, the largest contributors to Sumitomo Pharma's Scope 3 emissions were:
- Purchased Goods and Services (Cat. 1): 305,002 tCOâ‚‚e (85.62%)
- Capital Goods (Cat. 2): 18,623 tCOâ‚‚e (5.23%)
- Fuel- and Energy-Related Services (Cat. 3): 15,017 tCOâ‚‚e (4.22%)
Sumitomo Pharma's Scope 3 Emissions by Categories
Insights into Sumitomo Pharma's Total Carbon Footprint
In 2023, Sumitomo Pharma reported a total carbon footprint of 410,134 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 2.57% decrease compared to 2022, indicating progress in reducing its overall greenhouse gas output.
The largest contributor to Sumitomo Pharma's total carbon footprint was Scope 3 emissions, accounting for 86.85% of the company's total carbon footprint, followed by Scope 1 emissions at 6.61%.